{"id":"polystyrene-sulfonate","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Anorexia"},{"rate":null,"effect":"Gastric irritation"}]},"_chembl":{"chemblId":"CHEMBL1201484","moleculeType":"Small molecule"},"_dailymed":{"setId":"8bbeae67-a7ff-4fa6-b21e-fb8617cd9197","title":"SODIUM POLYSTYRENE SULFONATE SUSPENSION [BUREL PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by exchanging sodium ions for potassium ions as it passes through the intestines, effectively trapping potassium in the resin matrix. This reduces serum potassium levels by preventing potassium reabsorption and promoting fecal elimination. It is used to treat hyperkalemia (elevated blood potassium levels).","oneSentence":"Polystyrene sulfonate is an ion-exchange resin that binds potassium in the gastrointestinal tract, facilitating its removal from the body through feces.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:05:21.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Polystyrene_sulfonate","title":"Polystyrene sulfonate","extract":"Polystyrene sulfonates are a group of medications used to treat high blood potassium. Therapeutic effects generally appear hours to days after commencement of therapy. Common side effects include loss of appetite, gastrointestinal upset, constipation, and low blood calcium. Polystyrene sulfonates are given by mouth with a meal, or rectally by retention enema. Oral formulations often also contain the laxative sorbitol in order to lessen the risk of constipation which can be severe."},"indications":{"approved":[{"name":"Hyperkalemia (elevated serum potassium)"}]},"trialDetails":[{"nctId":"NCT03113981","phase":"NA","title":"Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Societe ACTIVBIOMAT","startDate":"2017-05-08","conditions":"Osteoarthritis, Hip, Coxarthrosis; Primary, Coxarthrosis; Secondary","enrollment":340},{"nctId":"NCT04585542","phase":"PHASE4","title":"Comparison of Potassium Binders in the ER","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-10-20","conditions":"Acute Hyperkalemia, Oral Potassium Binders","enrollment":37},{"nctId":"NCT04789239","phase":"PHASE2","title":"OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Fu","startDate":"2021-09-01","conditions":"Heart Failure, Hyperkalemia","enrollment":110},{"nctId":"NCT03305549","phase":"NA","title":"Recovery After Dialysis-Requiring Acute Kidney Injury","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-09-29","conditions":"Acute Kidney Injury","enrollment":16},{"nctId":"NCT06029179","phase":"NA","title":"SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-15","conditions":"Hyperkalemia","enrollment":120},{"nctId":"NCT06218212","phase":"NA","title":"The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-12","conditions":"Acute Kidney Injury","enrollment":24},{"nctId":"NCT04566653","phase":"","title":"Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-23","conditions":"Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure","enrollment":147},{"nctId":"NCT04440696","phase":"PHASE1, PHASE2","title":"To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder","status":"UNKNOWN","sponsor":"Grand Life Science (Liaoning) Co., Ltd.","startDate":"2020-10-21","conditions":"Hyperphosphatemia","enrollment":48},{"nctId":"NCT02065076","phase":"PHASE4","title":"Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients","status":"COMPLETED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2014-02","conditions":"Hyperkalemia, Chronic Kidney Failure","enrollment":38},{"nctId":"NCT01866709","phase":"PHASE4","title":"Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia","status":"TERMINATED","sponsor":"ZS Pharma, Inc.","startDate":"2013-05","conditions":"Hyperkalemia","enrollment":32},{"nctId":"NCT00004328","phase":"PHASE2","title":"Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1992-12","conditions":"Pseudohypoaldosteronism","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20120925","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"19921104","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"20180129","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"20001031","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"19890119","type":"ORIG","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"19911204","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA089910"},{"date":"20200225","type":"SUPPL","sponsor":"EPIC PHARMA LLC","applicationNumber":"ANDA202333"},{"date":"20140319","type":"ORIG","sponsor":"EPIC PHARMA LLC","applicationNumber":"ANDA202333"},{"date":"20200221","type":"SUPPL","sponsor":"KVK TECH","applicationNumber":"ANDA040905"},{"date":"20111108","type":"SUPPL","sponsor":"KVK TECH","applicationNumber":"ANDA040905"},{"date":"20090330","type":"ORIG","sponsor":"KVK TECH","applicationNumber":"ANDA040905"},{"date":"19910531","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20040318","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19890718","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19870716","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19851212","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19830427","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20110624","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20110303","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19911212","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"19821208","type":"ORIG","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20001130","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20110303","type":"SUPPL","sponsor":"CMP PHARMA INC","applicationNumber":"ANDA087859"},{"date":"20160218","type":"ORIG","sponsor":"CHARTWELL RX","applicationNumber":"ANDA206815"},{"date":"20200221","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA206815"}],"publicationCount":1387,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"polystyrene sulfonate","genericName":"polystyrene sulfonate","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Polystyrene sulfonate is an ion-exchange resin that binds potassium in the gastrointestinal tract, facilitating its removal from the body through feces. Used for Hyperkalemia (elevated serum potassium).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}